Profil de l'entreprise · Healthcare

Pharmaron Beijing Co Ltd

300759 · Shenzhen
Autres cotations3759 · Hong Kong
Bourse
Shenzhen
Pays / Région
China
Effectif
25 088
Cours actuel
¥38.77
En direct · 27 juillet 2026
Achat raisonnable
≤ ¥25
Point d'entrée avec marge de sécurité
Score de croissance Baillie
55/100
Moyen
Valeur intrinsèque · Fourchette en trois niveaux Cours actuel ¥38.77 En direct · Entre la fourchette raisonnable et la fourchette optimiste

Fourchette de valorisation composite · prudent ¥22–¥25 / raisonnable ¥28–¥35 / optimiste ¥41–¥47. À ¥38.77, Entre la fourchette raisonnable et la fourchette optimiste.

À la publication ¥29.11 (3 juillet 2026)

29 avril 2026 Contract Confirmed

一季度新签订单同比增长超过30%

The company said Q1 new orders grew over 30% YoY, with small-molecule CDMO orders up over 50%.

Possible impact:May affect views on future revenue recognition and CDMO demand momentum.

康龙化成View source
29 avril 2026 Earnings Confirmed

康龙化成披露2026年一季度业绩

Q1 2026 revenue rose 15.48% to RMB3.58bn; attributable net profit rose 9.75% to RMB335m.

Possible impact:May affect expectations for full-year growth, margin resilience and order conversion.

康龙化成View source
31 mars 2026 Contract Confirmed

制剂CDMO签订国际大型药企战略合作

Pharmaron said its Beijing formulation commercial facility was completed and signed a GLP-1 manufacturing partnership with a major global pharma.

Possible impact:May affect expectations for formulation CDMO commercialization capability and customer quality.

康龙化成View source
31 mars 2026 Earnings Confirmed

康龙化成发布2025年年度报告

2025 revenue rose 14.82% to RMB14.10bn; attributable net profit fell 7.22%, while recurring net profit rose 38.85%.

Possible impact:May affect views on core business recovery, one-off items and earnings quality.

康龙化成View source
28 mars 2026 Earnings Needs review

康龙化成披露2025年年度报告

Pharmaron released its 2025 annual report covering operations, R&D spending, segment performance and cash flow.

Possible impact:May shape expectations for CRO demand, cost control and medium-term growth quality.

巨潮资讯网View source

Automatically summarized from public sources; for context only, not investment advice.

Capitalisation70,79 Md CNY
Chiffre d'affaires (TTM)14,57 Md CNY
EBITDA3,11 Md CNY
Marge nette11,62 %
ROE9,99 %
PER (TTM)40,56
PER prévisionnel32,89
BPA0,95 CNY
Rendement du dividende0,51 %
Fourchette sur 52 semaines20,87 CNY – 42,00 CNY

Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Historique

Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.

Position dans le secteur

Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.